Peritoneal Dialysis System with Closed-Loop Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Peritoneal dialysis (PD) patients, especially diabetics, face challenges with glucose absorption from the dialysate leading to hyperglycemia, fluid overload, and peritoneal fibrosis, which complicates the management of fluid balance and glycemic control.
Innovation Solution
A PD system integrated with a glucose sensor and an insulin pump, controlled by a computing device with control circuitry, operates in a closed-loop manner to monitor blood glucose levels and adjust insulin delivery and PD therapy parameters, such as dialysate glucose concentration and dwell time, to maintain glycemic control and optimize ultrafiltration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If PD dialysate with glucose is delivered to the peritoneal cavity, then ultrafiltration is enhanced, but blood glucose level increases leading to hyperglycemia
Solution Approach 1:
The system continuously monitors blood glucose levels via a glucose sensor and uses this feedback to automatically adjust insulin delivery through the insulin pump. The control circuitry receives glucose level signals and modulates insulin dosage in real-time, creating a closed-loop control system that maintains glycemic control while preserving ultrafiltration efficacy
Solution Approach 2:
Insulin acts as an intermediary substance that mediates between the harmful effect of glucose absorption from dialysate and the desired outcome of glycemic control. The insulin pump delivers insulin as a counterbalancing agent that facilitates glucose uptake by tissues, thereby mitigating the hyperglycemic effect while allowing continued use of glucose-containing dialysate for ultrafiltration
2Quantity of substance
If high glucose concentration dialysate is used, then ultrafiltration volume increases, but glucose absorption by patient increases
Solution Approach 1:
The glucose sensor continuously monitors blood glucose levels and provides feedback to the control circuitry, which adjusts insulin delivery accordingly. This real-time monitoring and adjustment system allows the patient to tolerate higher glucose concentration dialysate for increased ultrafiltration volume while preventing excessive glucose absorption through automated insulin compensation
Solution Approach 2:
The system dynamically changes the parameter of insulin dosage based on measured blood glucose levels and ultrafiltration requirements. By adjusting insulin delivery parameters in response to glucose concentration in dialysate and actual glucose absorption, the system optimizes the balance between achieving sufficient ultrafiltration volume and minimizing net glucose load to the patient
3Productivity
If PD therapy is continued despite high blood glucose, then fluid management is maintained, but peritoneal fibrosis risk increases
Solution Approach 1:
The closed-loop system continuously monitors blood glucose levels and provides real-time feedback to adjust insulin delivery and PD therapy parameters. This prevents sustained hyperglycemia during PD therapy by automatically compensating with insulin, thereby maintaining fluid management efficacy while reducing the risk of peritoneal fibrosis associated with prolonged high glucose exposure
Solution Approach 2:
The system performs preliminary insulin delivery before or during the onset of hyperglycemia from dialysate glucose absorption. By proactively administering insulin based on predicted glucose load from the dialysate and real-time glucose monitoring, the system prevents the development of harmful hyperglycemic states that could lead to peritoneal fibrosis while maintaining continuous fluid management
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This integrated system improves the efficacy of PD therapy by maintaining blood glucose levels within a predetermined range, reducing glucose absorption, and enhancing ultrafiltration, thereby improving fluid management and reducing the risk of peritoneal fibrosis.
Implementation Method 1
a glucose sensor is configured to generate a signal indicative of a blood glucose level of the patient
Implementation Method 2
The peritoneum of the patient acts as a membrane through which waste products are removed from the blood of the patient via osmosis and diffusion
Implementation Method 3
The peritoneum of the patient acts as a membrane through which waste products are removed from the blood of the patient via osmosis and diffusion
Data Source
AI summary
In some examples, a system includes a glucose sensor configured to generate a signal indicative of a blood glucose level of a patient, a medical device configured to deliver insulin to the patient, a peritoneal dialysis (PD) device, and control circuitry. The control circuitry is configured to control the PD device to deliver PD therapy to a patient during a PD cycle, determine a blood glucose level of the patient during the PD cycle based on a signal from the glucose sensor, determine that the blood glucose level is greater than or equal to a predetermined blood glucose level threshold, and control the medical device to deliver insulin to the patient in response to determining the blood glucose level is greater than or equal to the predetermined blood glucose level threshold.